National Institute of Allergy and Infectious Diseases (NIAID) Clinical Site Monitoring Center (CSMC)

Closed Solicitation Posted

This opportunity was awarded. See the award notice from .

Solicitation number
75N93020R00021
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Place of performance
United States

Notice details come from SAM.gov. Updated .

About this opportunity

Written by GovTribe AI ·

The National Institute of Allergy and Infectious Diseases seeks to engage a contractor to provide comprehensive clinical site monitoring services for a range of clinical research programs and studies, including clinical trials related to immune-mediated diseases. The contractor must maintain a clinical site monitoring system, develop training programs, manage a centralized data reporting system, coordinate with other research support contractors and grantees, engage in risk-based monitoring innovation, and implement quality assurance controls. Proposals are due by May 24, 2021 and will be evaluated based on technical approach, management approach, and past performance. Four amendments provide additional clarification.

There is no set-aside designation. The primary NAICS code is 541715 and PSC code R425. The contractor must monitor both domestic and international clinical research sites over a base year plus seven optional periods of performance, providing 41,600 labor hours annually with potential increases. The place of performance is the United States.

Notice text

5 versions

Update #5 · Latest ·

Please see attached Amendment 4, revised answer to question #14.

The deadline for submitting questions has passed.

The RFP is attached for this solicitation.

Introduction

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID Division of Allergy, Immunology, and Transplantation has a requirement for a clinical site monitoring center.

Description

Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS), strives to better understand, treat, and ultimately prevent immunologic, infectious, and allergic diseases. The NIAID Division of Allergy, Immunology, and Transplantation (DAIT) supports extramural basic, pre-clinical, and clinical research focusing on protective immune responses and immune-mediated diseases through a variety of research grants and contracts. This includes support for clinical research programs and individual research projects to 1) evaluate the safety and efficacy of therapeutic and preventive approaches and agents, and 2) elucidate the underlying mechanisms of such approaches and agents.

A critical component of DAIT’s awarded grants and contracts involves the design and conduct of clinical research studies, including Phase 1 through 4 clinical trials of investigational approaches, intended to lead to a functional state of immune tolerance in three main clinical areas: autoimmune diseases; asthma and allergic diseases; and immune-mediated rejection of transplanted solid organs, tissues, and cells.

Purpose and Objectives

The purpose of this acquisition is to:

  1. Provide an expanded, wide range of clinical site monitoring services for NIAID-funded clinical research/trials of immune-mediated diseases, including as examples the delivery of monitoring services for:
  • the Immune Tolerance Network (ITN)
  • Asthma and Allergic Diseases Clinical Research Programs:
    • Asthma and Allergic Diseases Cooperative Research Centers (AADCRC)
    • Atopic Dermatitis Research Network (ADRN)
    • Consortium for Food Allergy Research (CoFAR)
    • Inner City Asthma Consortium (ICAC), which is to be replaced in 2021 by the Childhood Asthma in Urban Settings Clinical Research Network (CAUSE CRN)
  • Autoimmunity Centers of Excellence (ACE)
  • Transplantation Clinical Research Programs:
    • Clinical Trials in Organ Transplantation (CTOT) and in Children (CTOT-C), both of which will be replaced in Fiscal Year (FY) 2021 by the Clinical Trials in Organ Transplantation-Children and Adults (CTOT-CA)
  • Non-network clinical research/trials on a limited, as-needed basis, and
  • Unanticipated NIAID clinical research studies/trials that may be required in response to public health emergencies and/or emerging needs.

2. Advance the field of risk-based monitoring through innovation using novel and effective approaches, with the goal of ensuring participant safety, quality data, and greater site/study compliance.

Project requirements

The Contractor shall provide comprehensive clinical site and study monitoring services for a broad range of NIAID-sponsored and/or -funded clinical research (including but not limited to clinical trials) for both domestic and international research. The contractor will be responsible for:

  1. Clinical Site Monitoring System: Maintain a system to monitor domestic and international clinical research sites with respect to ensuring their adherence to regulatory requirements governing human subjects research, ICH E6(R2) Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), country- and state-specific requirements governing human subjects research, protocol-specific requirements, and NIAID policies and procedures;
     
  2. Training: Develop and implement training programs for clinical site personnel and site monitors;
     
  3. CSMC Data Management and Reporting System: Manage, maintain and update, as necessary, a centralized 21 CFR Part 11 compliant CSMC Data Management and Reporting System, using commercially available software, for the storage, quality control and retrieval of contract-generated data, reports and other materials, and for reporting on contract activities and the findings of the clinical site assessment and monitoring functions performed;
     
  4. Coordination and Collaboration with other NIAID Clinical Research Support Contractors and Grantees: At the direction of NIAID, the Contractor shall collaborate and coordinate with NIAID contractors, grantees, and partners on an as needed basis, in order to carry out clinical site and study monitoring and reporting responsibilities;
     
  5. Risk-Based Monitoring Innovation: At the direction of the COR, engage in the conduct of risk-based monitoring research that applies technological and effective solutions, with the goal of advancing strategic approaches that improve efficiencies in process and outcomes, with the outcome of increased participant safety, quality data and greater site/study compliance;
     
  6. Quality Assurance and Quality Control: Develop and implement a Quality Assurance/Quality Control (QA/QC) Plan designed to: (i) standardize contract processes; (ii) ensure that the conduct of all contract activities complies with domestic and country-specific regulations governing human subjects research, ICH GCP guidelines, and NIAID policies and procedures; and (iii) provide for the assessment of Contractor performance and the quality of clinical site monitoring activities conducted;
     
  7. Clinical, Scientific and Technical Personnel: The Contractor shall provide a Principal Investigator (PI)/Project Director with responsibility for overall project management and communications, tracking performance and cost, and monitoring and reporting on project status and progress. The PI/Project Director will ensure that the clinical, scientific, and technical personnel have the relevant individual education, training, expertise, experience, and qualifications required for the successful completion of contract requirements;
     
  8. Facilities, Equipment and Other Resources: The Contractor shall provide all facilities, equipment and other resources necessary to carry out the requirements of the contract.
Update #4 ·

Please see attached Amendment 3.

The deadline for submitting questions is has passed.

The RFP is attached for this solicitation.

Introduction

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID Division of Allergy, Immunology, and Transplantation has a requirement for a clinical site monitoring center.

Description

Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS), strives to better understand, treat, and ultimately prevent immunologic, infectious, and allergic diseases. The NIAID Division of Allergy, Immunology, and Transplantation (DAIT) supports extramural basic, pre-clinical, and clinical research focusing on protective immune responses and immune-mediated diseases through a variety of research grants and contracts. This includes support for clinical research programs and individual research projects to 1) evaluate the safety and efficacy of therapeutic and preventive approaches and agents, and 2) elucidate the underlying mechanisms of such approaches and agents.

A critical component of DAIT’s awarded grants and contracts involves the design and conduct of clinical research studies, including Phase 1 through 4 clinical trials of investigational approaches, intended to lead to a functional state of immune tolerance in three main clinical areas: autoimmune diseases; asthma and allergic diseases; and immune-mediated rejection of transplanted solid organs, tissues, and cells.

Purpose and Objectives

The purpose of this acquisition is to:

  1. Provide an expanded, wide range of clinical site monitoring services for NIAID-funded clinical research/trials of immune-mediated diseases, including as examples the delivery of monitoring services for:
  • the Immune Tolerance Network (ITN)
  • Asthma and Allergic Diseases Clinical Research Programs:
    • Asthma and Allergic Diseases Cooperative Research Centers (AADCRC)
    • Atopic Dermatitis Research Network (ADRN)
    • Consortium for Food Allergy Research (CoFAR)
    • Inner City Asthma Consortium (ICAC), which is to be replaced in 2021 by the Childhood Asthma in Urban Settings Clinical Research Network (CAUSE CRN)
  • Autoimmunity Centers of Excellence (ACE)
  • Transplantation Clinical Research Programs:
    • Clinical Trials in Organ Transplantation (CTOT) and in Children (CTOT-C), both of which will be replaced in Fiscal Year (FY) 2021 by the Clinical Trials in Organ Transplantation-Children and Adults (CTOT-CA)
  • Non-network clinical research/trials on a limited, as-needed basis, and
  • Unanticipated NIAID clinical research studies/trials that may be required in response to public health emergencies and/or emerging needs.

2. Advance the field of risk-based monitoring through innovation using novel and effective approaches, with the goal of ensuring participant safety, quality data, and greater site/study compliance.

Project requirements

The Contractor shall provide comprehensive clinical site and study monitoring services for a broad range of NIAID-sponsored and/or -funded clinical research (including but not limited to clinical trials) for both domestic and international research. The contractor will be responsible for:

  1. Clinical Site Monitoring System: Maintain a system to monitor domestic and international clinical research sites with respect to ensuring their adherence to regulatory requirements governing human subjects research, ICH E6(R2) Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), country- and state-specific requirements governing human subjects research, protocol-specific requirements, and NIAID policies and procedures;
     
  2. Training: Develop and implement training programs for clinical site personnel and site monitors;
     
  3. CSMC Data Management and Reporting System: Manage, maintain and update, as necessary, a centralized 21 CFR Part 11 compliant CSMC Data Management and Reporting System, using commercially available software, for the storage, quality control and retrieval of contract-generated data, reports and other materials, and for reporting on contract activities and the findings of the clinical site assessment and monitoring functions performed;
     
  4. Coordination and Collaboration with other NIAID Clinical Research Support Contractors and Grantees: At the direction of NIAID, the Contractor shall collaborate and coordinate with NIAID contractors, grantees, and partners on an as needed basis, in order to carry out clinical site and study monitoring and reporting responsibilities;
     
  5. Risk-Based Monitoring Innovation: At the direction of the COR, engage in the conduct of risk-based monitoring research that applies technological and effective solutions, with the goal of advancing strategic approaches that improve efficiencies in process and outcomes, with the outcome of increased participant safety, quality data and greater site/study compliance;
     
  6. Quality Assurance and Quality Control: Develop and implement a Quality Assurance/Quality Control (QA/QC) Plan designed to: (i) standardize contract processes; (ii) ensure that the conduct of all contract activities complies with domestic and country-specific regulations governing human subjects research, ICH GCP guidelines, and NIAID policies and procedures; and (iii) provide for the assessment of Contractor performance and the quality of clinical site monitoring activities conducted;
     
  7. Clinical, Scientific and Technical Personnel: The Contractor shall provide a Principal Investigator (PI)/Project Director with responsibility for overall project management and communications, tracking performance and cost, and monitoring and reporting on project status and progress. The PI/Project Director will ensure that the clinical, scientific, and technical personnel have the relevant individual education, training, expertise, experience, and qualifications required for the successful completion of contract requirements;
     
  8. Facilities, Equipment and Other Resources: The Contractor shall provide all facilities, equipment and other resources necessary to carry out the requirements of the contract.
Update #3 ·

Please see attached Amenment 2.

The deadline for submitting questions is April 26, 2021.

The RFP is attached for this solicitation.

Introduction

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID Division of Allergy, Immunology, and Transplantation has a requirement for a clinical site monitoring center.

Description

Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS), strives to better understand, treat, and ultimately prevent immunologic, infectious, and allergic diseases. The NIAID Division of Allergy, Immunology, and Transplantation (DAIT) supports extramural basic, pre-clinical, and clinical research focusing on protective immune responses and immune-mediated diseases through a variety of research grants and contracts. This includes support for clinical research programs and individual research projects to 1) evaluate the safety and efficacy of therapeutic and preventive approaches and agents, and 2) elucidate the underlying mechanisms of such approaches and agents.

A critical component of DAIT’s awarded grants and contracts involves the design and conduct of clinical research studies, including Phase 1 through 4 clinical trials of investigational approaches, intended to lead to a functional state of immune tolerance in three main clinical areas: autoimmune diseases; asthma and allergic diseases; and immune-mediated rejection of transplanted solid organs, tissues, and cells.

Purpose and Objectives

The purpose of this acquisition is to:

  1. Provide an expanded, wide range of clinical site monitoring services for NIAID-funded clinical research/trials of immune-mediated diseases, including as examples the delivery of monitoring services for:
  • the Immune Tolerance Network (ITN)
  • Asthma and Allergic Diseases Clinical Research Programs:
    • Asthma and Allergic Diseases Cooperative Research Centers (AADCRC)
    • Atopic Dermatitis Research Network (ADRN)
    • Consortium for Food Allergy Research (CoFAR)
    • Inner City Asthma Consortium (ICAC), which is to be replaced in 2021 by the Childhood Asthma in Urban Settings Clinical Research Network (CAUSE CRN)
  • Autoimmunity Centers of Excellence (ACE)
  • Transplantation Clinical Research Programs:
    • Clinical Trials in Organ Transplantation (CTOT) and in Children (CTOT-C), both of which will be replaced in Fiscal Year (FY) 2021 by the Clinical Trials in Organ Transplantation-Children and Adults (CTOT-CA)
  • Non-network clinical research/trials on a limited, as-needed basis, and
  • Unanticipated NIAID clinical research studies/trials that may be required in response to public health emergencies and/or emerging needs.

2. Advance the field of risk-based monitoring through innovation using novel and effective approaches, with the goal of ensuring participant safety, quality data, and greater site/study compliance.

Project requirements

The Contractor shall provide comprehensive clinical site and study monitoring services for a broad range of NIAID-sponsored and/or -funded clinical research (including but not limited to clinical trials) for both domestic and international research. The contractor will be responsible for:

  1. Clinical Site Monitoring System: Maintain a system to monitor domestic and international clinical research sites with respect to ensuring their adherence to regulatory requirements governing human subjects research, ICH E6(R2) Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), country- and state-specific requirements governing human subjects research, protocol-specific requirements, and NIAID policies and procedures;
     
  2. Training: Develop and implement training programs for clinical site personnel and site monitors;
     
  3. CSMC Data Management and Reporting System: Manage, maintain and update, as necessary, a centralized 21 CFR Part 11 compliant CSMC Data Management and Reporting System, using commercially available software, for the storage, quality control and retrieval of contract-generated data, reports and other materials, and for reporting on contract activities and the findings of the clinical site assessment and monitoring functions performed;
     
  4. Coordination and Collaboration with other NIAID Clinical Research Support Contractors and Grantees: At the direction of NIAID, the Contractor shall collaborate and coordinate with NIAID contractors, grantees, and partners on an as needed basis, in order to carry out clinical site and study monitoring and reporting responsibilities;
     
  5. Risk-Based Monitoring Innovation: At the direction of the COR, engage in the conduct of risk-based monitoring research that applies technological and effective solutions, with the goal of advancing strategic approaches that improve efficiencies in process and outcomes, with the outcome of increased participant safety, quality data and greater site/study compliance;
     
  6. Quality Assurance and Quality Control: Develop and implement a Quality Assurance/Quality Control (QA/QC) Plan designed to: (i) standardize contract processes; (ii) ensure that the conduct of all contract activities complies with domestic and country-specific regulations governing human subjects research, ICH GCP guidelines, and NIAID policies and procedures; and (iii) provide for the assessment of Contractor performance and the quality of clinical site monitoring activities conducted;
     
  7. Clinical, Scientific and Technical Personnel: The Contractor shall provide a Principal Investigator (PI)/Project Director with responsibility for overall project management and communications, tracking performance and cost, and monitoring and reporting on project status and progress. The PI/Project Director will ensure that the clinical, scientific, and technical personnel have the relevant individual education, training, expertise, experience, and qualifications required for the successful completion of contract requirements;
     
  8. Facilities, Equipment and Other Resources: The Contractor shall provide all facilities, equipment and other resources necessary to carry out the requirements of the contract.
Update #2 ·

Please see attached Amenment 1.

The deadline for submitting questions is April 26, 2021.

The RFP is attached for this solicitation.

Introduction

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID Division of Allergy, Immunology, and Transplantation has a requirement for a clinical site monitoring center.

Description

Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS), strives to better understand, treat, and ultimately prevent immunologic, infectious, and allergic diseases. The NIAID Division of Allergy, Immunology, and Transplantation (DAIT) supports extramural basic, pre-clinical, and clinical research focusing on protective immune responses and immune-mediated diseases through a variety of research grants and contracts. This includes support for clinical research programs and individual research projects to 1) evaluate the safety and efficacy of therapeutic and preventive approaches and agents, and 2) elucidate the underlying mechanisms of such approaches and agents.

A critical component of DAIT’s awarded grants and contracts involves the design and conduct of clinical research studies, including Phase 1 through 4 clinical trials of investigational approaches, intended to lead to a functional state of immune tolerance in three main clinical areas: autoimmune diseases; asthma and allergic diseases; and immune-mediated rejection of transplanted solid organs, tissues, and cells.

Purpose and Objectives

The purpose of this acquisition is to:

  1. Provide an expanded, wide range of clinical site monitoring services for NIAID-funded clinical research/trials of immune-mediated diseases, including as examples the delivery of monitoring services for:
  • the Immune Tolerance Network (ITN)
  • Asthma and Allergic Diseases Clinical Research Programs:
    • Asthma and Allergic Diseases Cooperative Research Centers (AADCRC)
    • Atopic Dermatitis Research Network (ADRN)
    • Consortium for Food Allergy Research (CoFAR)
    • Inner City Asthma Consortium (ICAC), which is to be replaced in 2021 by the Childhood Asthma in Urban Settings Clinical Research Network (CAUSE CRN)
  • Autoimmunity Centers of Excellence (ACE)
  • Transplantation Clinical Research Programs:
    • Clinical Trials in Organ Transplantation (CTOT) and in Children (CTOT-C), both of which will be replaced in Fiscal Year (FY) 2021 by the Clinical Trials in Organ Transplantation-Children and Adults (CTOT-CA)
  • Non-network clinical research/trials on a limited, as-needed basis, and
  • Unanticipated NIAID clinical research studies/trials that may be required in response to public health emergencies and/or emerging needs.

2. Advance the field of risk-based monitoring through innovation using novel and effective approaches, with the goal of ensuring participant safety, quality data, and greater site/study compliance.

Project requirements

The Contractor shall provide comprehensive clinical site and study monitoring services for a broad range of NIAID-sponsored and/or -funded clinical research (including but not limited to clinical trials) for both domestic and international research. The contractor will be responsible for:

  1. Clinical Site Monitoring System: Maintain a system to monitor domestic and international clinical research sites with respect to ensuring their adherence to regulatory requirements governing human subjects research, ICH E6(R2) Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), country- and state-specific requirements governing human subjects research, protocol-specific requirements, and NIAID policies and procedures;
     
  2. Training: Develop and implement training programs for clinical site personnel and site monitors;
     
  3. CSMC Data Management and Reporting System: Manage, maintain and update, as necessary, a centralized 21 CFR Part 11 compliant CSMC Data Management and Reporting System, using commercially available software, for the storage, quality control and retrieval of contract-generated data, reports and other materials, and for reporting on contract activities and the findings of the clinical site assessment and monitoring functions performed;
     
  4. Coordination and Collaboration with other NIAID Clinical Research Support Contractors and Grantees: At the direction of NIAID, the Contractor shall collaborate and coordinate with NIAID contractors, grantees, and partners on an as needed basis, in order to carry out clinical site and study monitoring and reporting responsibilities;
     
  5. Risk-Based Monitoring Innovation: At the direction of the COR, engage in the conduct of risk-based monitoring research that applies technological and effective solutions, with the goal of advancing strategic approaches that improve efficiencies in process and outcomes, with the outcome of increased participant safety, quality data and greater site/study compliance;
     
  6. Quality Assurance and Quality Control: Develop and implement a Quality Assurance/Quality Control (QA/QC) Plan designed to: (i) standardize contract processes; (ii) ensure that the conduct of all contract activities complies with domestic and country-specific regulations governing human subjects research, ICH GCP guidelines, and NIAID policies and procedures; and (iii) provide for the assessment of Contractor performance and the quality of clinical site monitoring activities conducted;
     
  7. Clinical, Scientific and Technical Personnel: The Contractor shall provide a Principal Investigator (PI)/Project Director with responsibility for overall project management and communications, tracking performance and cost, and monitoring and reporting on project status and progress. The PI/Project Director will ensure that the clinical, scientific, and technical personnel have the relevant individual education, training, expertise, experience, and qualifications required for the successful completion of contract requirements;
     
  8. Facilities, Equipment and Other Resources: The Contractor shall provide all facilities, equipment and other resources necessary to carry out the requirements of the contract.
Update #1 ·

The RFP is attached for this solicitation.

Introduction

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID Division of Allergy, Immunology, and Transplantation has a requirement for a clinical site monitoring center.

Description

Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS), strives to better understand, treat, and ultimately prevent immunologic, infectious, and allergic diseases. The NIAID Division of Allergy, Immunology, and Transplantation (DAIT) supports extramural basic, pre-clinical, and clinical research focusing on protective immune responses and immune-mediated diseases through a variety of research grants and contracts. This includes support for clinical research programs and individual research projects to 1) evaluate the safety and efficacy of therapeutic and preventive approaches and agents, and 2) elucidate the underlying mechanisms of such approaches and agents.

A critical component of DAIT’s awarded grants and contracts involves the design and conduct of clinical research studies, including Phase 1 through 4 clinical trials of investigational approaches, intended to lead to a functional state of immune tolerance in three main clinical areas: autoimmune diseases; asthma and allergic diseases; and immune-mediated rejection of transplanted solid organs, tissues, and cells.

Purpose and Objectives

The purpose of this acquisition is to:

  1. Provide an expanded, wide range of clinical site monitoring services for NIAID-funded clinical research/trials of immune-mediated diseases, including as examples the delivery of monitoring services for:
  • the Immune Tolerance Network (ITN)
  • Asthma and Allergic Diseases Clinical Research Programs:
    • Asthma and Allergic Diseases Cooperative Research Centers (AADCRC)
    • Atopic Dermatitis Research Network (ADRN)
    • Consortium for Food Allergy Research (CoFAR)
    • Inner City Asthma Consortium (ICAC), which is to be replaced in 2021 by the Childhood Asthma in Urban Settings Clinical Research Network (CAUSE CRN)
  • Autoimmunity Centers of Excellence (ACE)
  • Transplantation Clinical Research Programs:
    • Clinical Trials in Organ Transplantation (CTOT) and in Children (CTOT-C), both of which will be replaced in Fiscal Year (FY) 2021 by the Clinical Trials in Organ Transplantation-Children and Adults (CTOT-CA)
  • Non-network clinical research/trials on a limited, as-needed basis, and
  • Unanticipated NIAID clinical research studies/trials that may be required in response to public health emergencies and/or emerging needs.

2. Advance the field of risk-based monitoring through innovation using novel and effective approaches, with the goal of ensuring participant safety, quality data, and greater site/study compliance.

Project requirements

The Contractor shall provide comprehensive clinical site and study monitoring services for a broad range of NIAID-sponsored and/or -funded clinical research (including but not limited to clinical trials) for both domestic and international research. The contractor will be responsible for:

  1. Clinical Site Monitoring System: Maintain a system to monitor domestic and international clinical research sites with respect to ensuring their adherence to regulatory requirements governing human subjects research, ICH E6(R2) Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), country- and state-specific requirements governing human subjects research, protocol-specific requirements, and NIAID policies and procedures;
     
  2. Training: Develop and implement training programs for clinical site personnel and site monitors;
     
  3. CSMC Data Management and Reporting System: Manage, maintain and update, as necessary, a centralized 21 CFR Part 11 compliant CSMC Data Management and Reporting System, using commercially available software, for the storage, quality control and retrieval of contract-generated data, reports and other materials, and for reporting on contract activities and the findings of the clinical site assessment and monitoring functions performed;
     
  4. Coordination and Collaboration with other NIAID Clinical Research Support Contractors and Grantees: At the direction of NIAID, the Contractor shall collaborate and coordinate with NIAID contractors, grantees, and partners on an as needed basis, in order to carry out clinical site and study monitoring and reporting responsibilities;
     
  5. Risk-Based Monitoring Innovation: At the direction of the COR, engage in the conduct of risk-based monitoring research that applies technological and effective solutions, with the goal of advancing strategic approaches that improve efficiencies in process and outcomes, with the outcome of increased participant safety, quality data and greater site/study compliance;
     
  6. Quality Assurance and Quality Control: Develop and implement a Quality Assurance/Quality Control (QA/QC) Plan designed to: (i) standardize contract processes; (ii) ensure that the conduct of all contract activities complies with domestic and country-specific regulations governing human subjects research, ICH GCP guidelines, and NIAID policies and procedures; and (iii) provide for the assessment of Contractor performance and the quality of clinical site monitoring activities conducted;
     
  7. Clinical, Scientific and Technical Personnel: The Contractor shall provide a Principal Investigator (PI)/Project Director with responsibility for overall project management and communications, tracking performance and cost, and monitoring and reporting on project status and progress. The PI/Project Director will ensure that the clinical, scientific, and technical personnel have the relevant individual education, training, expertise, experience, and qualifications required for the successful completion of contract requirements;
     
  8. Facilities, Equipment and Other Resources: The Contractor shall provide all facilities, equipment and other resources necessary to carry out the requirements of the contract.

Files

File Type Posted
Amendment 4 to RFP Final.pdf PDF
Amendment 3 to RFP Final.pdf PDF
Amendment 2 to RFP Final.pdf PDF
Amendment 1 to RFP Final.pdf PDF
RFP 75N93020R00021 Final 2_23.pdf PDF

Notice history

Notice Type Posted
National Institute of Allergy and Infectious Diseases (NIAID) Clinical Site Monitoring Center (CSMC) Award Award Notice
This notice Latest solicitation Solicitation
National Institute of Allergy and Infectious Diseases (NIAID) Clinical Site Monitoring Center (CSMC) Pre-Solicitation
National Institute of Allergy and Infectious Diseases (NIAID) Clinical Site Monitoring Center (CSMC) Original Pre-Solicitation

Similar open opportunities

Opportunity Agency Set-aside Responses due
Pre-Clinical Models of Infectious Diseases United States · NAICS 541714 National Institute of Allergy and Infectious Diseases No set-aside
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases NAICS 541715 National Institute of Allergy and Infectious Diseases No set-aside
Clinical Research Support and Collaboration for NHGRI Protocols Bethesda, Maryland, United States · NAICS 541690 Office of Logisitics and Acquisition Operations Total Small Business
EmbraceHEALTH Clinical Research Network (EmbraceHEALTH CRN) - Coordinating Center Bethesda, Maryland, United States · NAICS 541715 National Institute of Child Health and Human Development No set-aside

See more similar opportunities on GovTribe

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity
Try for free Login

GovTribe for Federal Contractors